FGFR4 and hepatocellular carcinoma: A growing body of evidence has demonstrated that inhibitors targeting FGF/FGFR, including multikinase inhibitors, specialized FGFR4 inhibitors, and FGF ligand traps, exhibit antitumor activity in preclinical or early stages of HCC.35